1-(2-呋喃基)-2-丙胺 | 57580-64-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(2-呋喃基)-2-丙胺
• 英文名称: 1-(2-furyl)-2-aminopropane
• 英文别名: 1-(furan-2-yl)propan-2-amine；1-(2-Furyl)-2-aminopropan；2-Amino-1-
• CAS: 57580-64-0；83687-81-4；83687-84-7
• 化学式: C₇H₁₁NO
• mdl: MFCD05240377
• 分子量: 125.17
• InChiKey: IDUAQSPIDXGMKI-UHFFFAOYSA-N

物化性质

• 闪点：
  3 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  1-(2-呋喃基)-2-丙胺 、 2-(5-(3,4-dichloroquinolin-6-yl)pyrimidin-2-yl)propan-2-ol 在 caesium carbonate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 2.0h， 生成 2-(5-(3-chloro-4-((1-(furan-2-yl)propan-2-yl)amino)quinolin-6-yl)pyrimidin-2-yl)propan-2-ol
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA

  摘要：

  披露了公式(I)化合物或其盐，其中：A是CR1或N；B是CR3或N；D是CR4或N；L1是-(CR7R7)m-；L2是-(CR7R7)n-；X，Z，R1，R2，R3，R4，R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。

  公开号：

  WO2017023905A1
• 作为产物：
  描述：

  (E)-2-(2-nitroprop-1-en-1-yl)furan 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-(2-呋喃基)-2-丙胺
  参考文献：
  名称：

  Furyl- and Tetrahydrofuryl-alkylamines

  摘要：

  DOI：

  10.1021/jo01116a016

文献信息

• CYANOFLUOROPYRROLIDINE DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1627870A1

  公开（公告）日：2006-02-22

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R1 and R2 are as defined in the specification, X represents a single bond or a C1-3 alkylene group, and R3 represents a group represented by the formula: -N(R4)COR5, -N(R4)SO2R5, -NR4R6, -SO2R5, -SO2NR4R5, -OCONR4R5, -CH=CH-R7 or -C≡C-R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y3 group)].

  一个用于预防或治疗可以通过抑制二肽基肽酶IV（DPPIV）来改善的疾病或病症的氰基氟代吡咯烷化合物，其具有公式（I）或药用上可接受的盐或水合物： [其中 A代表氢原子或氟原子， R1和R2如说明书中定义， X代表单键或C1-3亚烷基，并且 R3代表由公式表示的基团：-N(R4)COR5，-N(R4)SO2R5，-NR4R6，-SO2R5，-SO2NR4R5，-OCONR4R5，-CH=CH-R7或-C≡C-R7，或代表从至少含有一个氧和/或硫原子，并可能进一步含有氮原子的杂芳基组中选择的一个杂芳基组，以及一个6-成员氮杂芳环或9至11-成员的稠环（其中杂芳基组可以与一个或多个来自代Y3基团的取代基取代）。]
• Monocyclic aroylpyridinones as antiinflammatory agents
  申请人：Alonso-Alija Cristina

  公开号：US20060046999A1

  公开（公告）日：2006-03-02

  The present invention relates to monocyclic aroylpyridinones, processes for their preparation, and their use in medicaments, especially for the treatment of COPD: (formula I).

  本发明涉及单环芳酰吡啶酮，其制备方法以及它们在药物中的应用，特别是用于慢性阻塞性肺疾病的治疗：（公式I）。
• Cyanofluoropyrrolidine derviative
  申请人：Fukushima Hiroshi

  公开号：US20060293297A1

  公开（公告）日：2006-12-28

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R 1 and R 2 are as defined in the specification, X represents a single bond or a C 13 alkylene group, and R 3 represents a group represented by the formula: —N(R 4 )COR 5 , —N(R 4 )SO 2 R 5 , —NR 4 R 6 , —SO 2 R 5 , —SO 2 NR 4 R 5 , —OCONR 4 R 5 , —CH═CH—R 7 or —C≡C—R 7 , or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y 3 group)].

  一种氰基氟吡咯烷化合物，化学式为(I)，或其药学上可接受的盐或水合物，能够作为一种抑制二肽基肽酶IV（DPPIV）并预防或治疗疾病或症状的药物，例如糖尿病，免疫性疾病等。其中A代表氢原子或氟原子，R1和R2如规范中所定义，X代表单键或C13烷基，R3代表由以下公式表示的基团：—N(R4)COR5，—N(R4)SO2R5，—NR4R6，—SO2R5，—SO2NR4R5，—OCONR4R5，—CH═CH—R7或—C≡C—R7，或表示从含有至少一个氧和/或硫原子的杂环芳基中选择的杂环芳基，该杂环芳基还可以包含一个氮原子以及一个6元氮含杂环芳基或9-11元的缩合环（其中杂环芳基可以用来代替一个或多个取代基Y3）。
• 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Barrow C. James

  公开号：US20080015233A1

  公开（公告）日：2008-01-17

  The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及2,4,6-取代吡啶衍生物化合物，其是beta-分泌酶酶的抑制剂，可用于治疗涉及beta-分泌酶酶的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及beta-分泌酶酶的这种疾病的治疗中的使用。
• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。